• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Teva Pharmaceutical Industries Limited Ordinary Shares (NY:TEVA)

    39.53 -0.28 (-0.70%)
    Streaming Delayed Price Updated: 10:19 AM EDT, Sep 30, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Teva Pharmaceutical Industries Limited Ordinary Shares

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    34 35 Next >
    News headline image
    Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround ↗
    Built on substance, not hype, Teva's mega rally is just getting started. 
    Via The Motley Fool
    News headline image
    Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Releases Q3 2026 Aide Memoire
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Eyes New Growth Phase After Securing Investment-Grade Ratings ↗
    Teva Pharmaceutical Industries (NYSE:TEVA) is planning for greater financial flexibility after receiving investment-grade ratings from all three major credit rating agencies, President and CEO Richard... 
    Via MarketBeat
    Topics Bankruptcy
    News headline image
    Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth Pipeline ↗
    Teva Pharmaceutical Industries (NYSE:TEVA) Chief Executive Officer Richard Francis said the company has shifted from being viewed primarily as a generics manufacturer toward a biopharmaceutical company... 
    Via MarketBeat
    News headline image
    New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Says Pivot to Growth Gains Steam as Branded Drugs, Biosimilars Outperform ↗
    Teva Pharmaceutical Industries (NYSE:TEVA) CEO Richard Francis said the company has progressed from the initial phase of its “Pivot to Growth” plan into its next stage, citing momentum in branded... 
    Via MarketBeat
    Topics World Trade
    News headline image
    Teva Pharmaceuticals Sees Pivot to Growth Accelerating on Branded Drugs, Biosimilars ↗
    Teva Pharmaceutical Industries (NYSE:TEVA) said its “Pivot to Growth” strategy has moved into its second phase, with management pointing to momentum in branded medicines, a stabilized generics... 
    Via MarketBeat
    News headline image
    Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Announces Launch of Offering of Senior Notes
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva’s TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study ↗
    Teva Pharmaceutical Industries (NYSE:TEVA) reported positive topline results from a Phase IIa gluten-challenge study of TEV-408, its anti-IL-15 antibody candidate for celiac disease, with the company... 
    Via MarketBeat
    News headline image
    Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva (TEVA) Q2 2026 Earnings Call Transcript ↗
    Key innovative brands now generate over $1B quarterly revenue. 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Why Teva Pharmaceutical Stock Surged This Week ↗
    Teva reported its Q2 results this week, but the stock's big gains mostly stemmed from another catalyst. 
    Via The Motley Fool
    Topics Stocks
    News headline image
    Teva Pharmaceutical Industries Q2 Earnings Call Highlights ↗
    Teva Pharmaceutical Industries (NYSE:TEVA) reported second-quarter 2026 revenue of approximately $4.1 billion, down 1% from a year earlier in U.S. dollars, as lower sales from generic Revlimid were... 
    Via MarketBeat
    Topics Earnings
    News headline image
    Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva's Turnaround Is Working. Here's the 1 Thing That Could Send It Soaring Another 50%. ↗
    The pharmaceutical company has a likely blockbuster drug as the flagship of its pipeline. 
    Via The Motley Fool
    News headline image
    Wall Street Thinks Teva Can Soar Over 60%. Here's Why Analysts Are Right. ↗
    The stock has a 100% buy rating from polled analysts, with some eye-catching price targets. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Teva Pharmaceutical Industries’ Anti-IL-15 Antibody Shows Promise in Vitiligo Study ↗
    Teva Pharmaceutical Industries (NYSE:TEVA) said its internally developed anti-IL-15 antibody produced encouraging 24-week efficacy results in a phase 1b proof-of-concept study for vitiligo, as the... 
    Via MarketBeat
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    34 35 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.